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Abstract
Background: Elastin microfibril interface located protein 2 (EMILIN2) is an extracellular glycoprotein associated with
cardiovascular development. While other EMILIN proteins are reported to play a role in elastogenesis and
coagulation, little is known about EMILIN2 function in the cardiovascular system. The objective of this study was to
determine whether EMILIN2 could play a role in thrombosis.
Results: EMILIN2 mRNA was expressed in 8 wk old C57BL/6J mice in lung, heart, aorta and bone marrow, with the
highest expression in bone marrow. In mouse cells, EMILIN2 mRNA expression in macrophages was higher than
expression in endothelial cells and fibroblasts. EMILIN2 was identified with cells and extracellular matrix by
immunohistochemistry in the carotid and aorta. After carotid ferric chloride injury, EMILIN2 was abundantly
expressed in the thrombus and inhibition of EMILIN2 increased platelet de-aggregation after ADP-stimulated
platelet aggregation.
Conclusions: These results suggest EMILIN2 could play a role in thrombosis as a constituent of the vessel wall
and/or a component of the thrombus.
Background
The clinical manifestations of arterial and venous
thrombosis represent the leading causes of death in the
developed world [1]. While arterial and venous throm-
bosis have fundamental pathobiological differences, both
are complex [2] and are influenced by multiple genetic
and environmental factors [3]. Acute thrombosis at the
site of a plaque is thought to be a precipitating event in
the transition from a stable or subclinical atherosclerotic
disease to acute myocardial infarction, ischemic stroke
or peripheral arterial occlusion. For individuals under-
going surgery, thromboembolism and venous thrombo-
sis are common. Twin and sibling studies [4] show that
inherited risk factors contribute significantly to the
development of coronary artery disease and ischemic
stroke. Genetic abnormalities that influence production,
activity, or metabolism can shift the balance in favor of
thrombosis. Polymorphisms [2,5] in coagulation factors,
fibrinolytic factors, platelet surface receptors, methylene-
tetrahydrofolate reductase, endothelial nitric oxide
synthase and antioxidant enzymes have been implicated
as genetic factors of risk for thrombosis. The role of
many of these risk factors in thrombotic diseases has
been replicated in animal models [6-11]. Great strides
have been made in the diagnosis and treatment of
thrombosis in the last decade. However, strategies to
prevent thrombosis have lagged far behind, due in part
to the contribution of multiple and as yet undefined
genetic factors that lead to thrombotic risk. The objec-
tive of this study was to investigate whether EMILIN2
(elastin microfibril interface located protein 2), distribu-
ted in the cardiovascular system during development
[12], plays a role in thrombosis.
T h eE M I L I Np r o t e i n sa r eag r o u po fe x t r a c e l l u l a r
matrix multimeric glycoproteins [13] including EMILIN1,
Multimerin1, Multimerin2 and EMILIN2. The EMILIN
proteins share four protein domains (Figure 1): C-term-
inal C1q domain, collagenous domain, coiled-coil domain
and N-terminal cysteine-rich domain (EMI domain). The
EMILIN proteins contain unique domains that are not
shared: EMILIN1 has two leucine zipper regions; multi-
merin has an endothelial growth factor-like domain; and
EMILIN2 contains a proline-rich domain. The domain
organization suggests some shared and some specific
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line-rich domain in EMILIN2 could provide structural
flexibility and unique protein-protein interacting sites.
EMILIN2 most closely resembles EMILIN1 [12], sharing
70% and 75% identity at the N- and C-terminal domains,
respectively. Mouse EMILIN2 [12] has 73% identity with
human EMILIN2.
While little is known about the function of EMILIN2,
functions have been identified for EMILIN1 and Multi-
merin1. The C1q domain is homologous to C1q domains
in a variety of proteins that are often involved in target-
ing proteins to cell surfaces and to other proteins [14].
C1q is the target recognition domain of the classical
pathway of complement activation and a connecting link
between the innate and acquired immunity systems [15].
The C1q domains bind to form homo- and hetero-multi-
mers. EMILIN2 can form heterotrimers with EMILIN1
and partially co-localizes with EMILIN1 in cell culture.
EMILIN1 deficient mice [16] are fertile, growth rate is
similar to wild-type mice, and they show no gross
abnormalities. However, they have hypertension, deficits
in elastogenesis, and defects of the lymphatic vasculature
[16,17]. In addition to its role in vascular elastic fiber
structure, EMILIN1 promotes cell adhesion and/or cell
migration of several soft tissue sarcomas and hemato-
poietic cells [12]. Studies have reported that the EMI-
LIN1 C1q domain mediates cell adhesion through a4b1
integrin [18]. Unlike other members of the EMILIN
family, Multimerin contains an RGD site and binds to
aIIb3 on platelets and avb3 on endothelial cells [19].
Cell adhesion to immobilized Multimerin1 involves
RGD-dependent and -independent mechanisms, depend-
ing on the cell type. The binding of endothelial cells, acti-
vated neutrophils and smooth muscle cells to Multimerin
is not RGD dependent. In addition, Multimerin1 [20] is
found as a complex with platelet factor V in platelet a-
granules and is released to the platelet surface upon pla-
telet activation. It is also present in endothelial cells. The
structural features of EMILIN1 and EMILIN2 suggest a
unique, but related function for EMILIN2 in vascular
homeostasis.
The major sites of expression of the EMILIN genes are
in the cardiovascular system [21-23]. Other elastin asso-
ciated binding proteins, including EMILIN1, fibulins and
fibrillins [24,25] are important for the integrity of the
vessel wall structure. EMILIN1 deficiency causes disrup-
tions of the endothelial cell layer and interruptions of
the elastic lamellae of large vessels [16]. Fibulin1 binds
to elastin and fibrinogen and is incorporated into fibrin
clots and atherosclerotic plaques [16]; fibulin1 deficiency
causes hemorrhaging due to the abnormal ECM; fibulin
5 deficient mice have altered vascular remodeling [26]
and fibulin4 deficient mice [26,27] are susceptible to
aneurysm formation and aortic valve abnormalities.
Hypertension is found in Emilin1 deficient mice and
numerous studies indicate that hypertension is a risk
factor for thrombosis. The association of these ECM
proteins in the vascular wall with vascular remodeling
after injury and hemostasis, implies that EMILIN2 may
also share these functions and points to a potential role
of EMILIN2 in thrombosis. The purpose of this study
was to assess whether EMILIN2 plays a role in
thrombosis.
T h er e s u l t so ft h i ss t u d yi n d i c a t et h a tE M I L I N 2d o e s
have the potential to regulate thrombosis. The major
source of Emilin2 expression is the bone marrow. EMI-
LIN2 is expressed in aorta, carotid artery wall, and ferric
chloride-induced thrombi. In addition, inhibition of
EMILIN2 causes de-aggregation of in vitro ADP-stimu-
lated platelets. This study suggests EMILIN2 may be a
modifier of thrombosis.
Methods
Mice
C57BL/6J mice (#000664) were obtained from Jackson
Laboratory (Bar Harbor, Maine) at 6 weeks of age. Mice
were housed at the Biological Resource Unit at the Cle-
veland Clinic Lerner Research Institute. Mice were
tested between 7 and 9 weeks of age. All animal experi-
ments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use
Committee at the Cleveland Clinic.
Cells and cell culture
The mouse cell lines, endothelial cells (EOMA), fibro-
blast cells (NIH3T3) and macrophage-like cells
(Raw264.7) were purchased from the ATCC Global Bio-
source Centre (Manassas, VA). The cells were main-
tained according to the guidelines for each cell line in
DMEM containing 10% FBS (Invitrogen, Carlsbad, CA)
at 37°C with 5% CO2 and harvested at 90% confluence.
Bone marrow was collected from the femurs and cells
Multimerin 
Emilin 2
Emilin 1 
Coiled-coil LZ
Coiled-coil EMI C1q COL  P
Coiled-coil EMI EGF C1q
EMI
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Figure 1 EMILIN Protein Domains. EMILIN2, EMILIN1 and
Multimerin protein domains. Modified from Leimeister et al. [22]
Grey: EMI (amino-terminal cysteine rich) domain; open: coiled-coil
domain; light blue: P (proline-rich) domains; light grey: COL
(collagen) domain, and green: C1q (complement component 1,
subcomponent q) domain.
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then washed with PBS.
RT-PCR and real-time PCR
Total RNA was purified from the tissues and the cells
using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA),
treated with TURBO DNase (Ambion, Austin, TX) and
reverse transcripted into cDNA using SuperScript™ III
First-Strand Synthesis System for RT-PCR (Invitrogen,
Carlsbad, CA) according to the manufacturer’si n s t r u c -
tions. RT-PCR was performed using 50 ng cDNA from
mice as templates. The PCR product was analyzed on
1% or 1.2% agarose gel and recovered by Qiaquick Gel
Extraction Kit (Qiagen). Sequencing (ABI 3730xl,
Applied Biosystems, Foster City, CA) was performed at
the Genomics Core of Cleveland Clinic. Negative con-
trols that omit reverse transcription were included.
Real-time PCR was performed using a BioRad iCycler
i Q( B i o R a d ,H e r c u l e s ,C A ) .E ach amplification reaction
contained 20 ng of cDNA, 300 nM of each primer,
25 μL of 2× power SYBR Green Master Mix (Applied
Biosystems, Warrington, UK), and 0.5 μLo fU N G
(Applied Biosystems) added to prevent carryovers. Sam-
ples were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Operon, Huntsville, AL). The
comparative cycle threshold method was used to analyze
the data. RNA was isolated from 5-6 mice for each
group and analyzed in triplicates.
FeCl3 carotid injury and immunohistochemical staining
To induce thrombus formation in the carotid artery, a
ferric chloride (FeCl3) model of vessel injury was
employed as previously described [28]. The flow probe
(Model 0.5PSB, Transonic Systems, Ithaca, NY) was in
place from baseline measurements to several minutes
after the stable occlusion had been reached, or stopped at
30 min if it had not occluded. Blood flow was recorded
every 10 sec (Model TS420, Transonic Systems). After
cardiac perfusion, the carotid arteries were harvested
after occlusion, immediately embedded into OCT
(Tissue-Tek, Torrance, CA) and frozen. The frozen caro-
tid arteries were sectioned at 10 μmu s i n gac r y o s t a t
(Leica CM1850, Leica Microsystems, Nassloch, Ger-
many), fixed with acetone at 4°C for 10 min then blocked
with normal serum. EMILIN2 was detected with E185
(rabbit anti-peptide antibody, see additional files 1 and 2)
or Q-16 (goat antibody, sc-51356, Santa Cruz Biotechnol-
ogy, CA), and P-selectin with rabbit anti-CD62P antibody
(BD biosciences, San Diego, CA). The sections were then
incubated with 1:1000 diluted biotinylated appropriate
secondary antibodies (PK-6101, PK-6105 Vectastain ABC
Kit, Vector Laboratories, Burlingame, CA) and proteins
were visualized with alkaline phosphatase substrate. For
quantification analysis, six sections of each carotid and
six mice from each group were measured and analyzed
using Image-Pro Plus (Media Cybernetics, Silver Spring,
MD).
Platelet aggregation assay
Blood was collected into sodium citrate from the vena
cava of anesthetized mice. The platelet rich plasma
(PRP) was collected by centrifugation at 100×g for
10 min, and cell pellets were centrifuged at 1000×g for
10 minutes to collect platelet poor plasma (PPP). Plate-
lets were counted using a Cellometer Auto M10 (Nexce-
lom Bioscience, Lawrence, MA) and adjusted with PPP
to 2-3×10
8/ml. PRP was incubated with 26 μg/ml anti-
EMILIN2 antibody E185, or at a concentration as indi-
cated, or control antibody (Calbiochem, La Jolla, CA)
f o r3m i n u t e sa t3 7 ° Cf o l l o w e db yt h ea d d i t i o no f
20 mM ADP (Chrono-log Corporation, Havertown, PA).
Platelet aggregation was measured in an aggregometer
(Chrono-log Corporation) and each sample was allowed
to run for 8 minutes with stirring at 37°C.
Statistical analysis
Differences between strains were determined by a t-test
or ANOVA with a Newman-Kuels Multiple Comparison
post-test. Data are presented as mean ± SEM.
Results
Distribution of Emilin2 mRNA in tissues
The mRNA expression of Emilin2 was determined by
quantitative real-time PCR in lung, heart, aorta and
bone marrow cells (Figure 2A). The expression in the
bone marrow was 20-fold higher than in the lung. This
suggests that bone marrow is a major source of Emilin2
and is unlike Emilin1 expression [21] where the major
source is the vessel wall.
Expression of Emilin2 was tested in a mouse macro-
phage-like cell line (Raw264.7), and two other cell types
associated with vascular wall, a mouse endothelial cell line
(EOMA), and a mouse fibroblast cell line (NIH3T3). The
relative expression in macrophage cells was comparable to
expression in mouse bone marrow cells (Figure 2B). The
expression of Emilin2 was 7-, 32- and 26-fold higher in
NIH3T3, Raw264.7 and bone marrow cells, respectively,
compared to EOMA cells suggesting that the expression
of Emilin2 may be high in hematopoietic progenitor stem
cells, precursors for white and red blood cells and
platelets.
EMILIN2 was expressed in the vessel wall and in the
thrombus induced by vascular injury
EMILIN2 was detected in the vessel wall of uninjured
carotids (Figure 3A, B). The immunostaining was 55% ±
2 of the vessel wall area (Figure 3G, gray bar). EMILIN2
was detected in both cells and extracellular matrix. The
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file 3). To determine if EMILIN2 protein is incorporated
into the thrombus, FeCl3 was used to induce thrombus
formation in the carotid artery. After injury, carotid
arteries were harvested and immunostained for EMI-
LIN2 (Figure 3C, D). Strong (77% ± 2) (Figure 3G open
bar) EMILIN2-specific staining was detected in thrombi,
suggesting that EMILIN2 is associated most strongly
with the thrombus rather than the vessel wall. This is
consistent with the mRNA expression in the bone mar-
row cells, platelet, and plasma protein expression. No
signal was detected in the sections stained with rabbit
IgG or pre-immune rabbit serum. The staining of EMI-
LIN2 in thrombi was confirmed by using the commer-
cial EMILIN2 Q-16 antibody (Figure 3E).
The high expression of EMILIN2 in bone marrow and
in the thrombi raised the question whether EMILIN2 was
involved in platelet function. Therefore, carotid sections
were also immunostained for P-selectin (Figure 3F), one
of the platelet markers. Strong immunostaining (Figure
3G, black bar) for P-selectin (88% ± 1 of thrombi area)
revealed a similar distribution pattern to that found for
EMILIN2 (77% of thrombi area) in the injured carotids.
EMILIN2 antibody inhibits platelet aggregation
The similar relative distribution of EMILIN2 and plate-
lets in the thrombi suggested that EMILIN2 may regulate
clot stability through a role in platelet aggregation. Pre-
incubation of platelets with anti-EMILIN2 antibody
inhibited the extent and rate of platelet aggregation
induced by ADP (Figure 4A). Pre-incubation of platelets
with EMILIN2 antibody inhibited the maximum ampli-
tude of platelet aggregation by approximately 42% (Figure
4B). Moreover, the EMILIN2 antibody caused platelet de-
aggregation in the presence of high ADP concentrations
(20 μM) over induction time (Figure 4C). At 7 minutes
after addition of 20 μM ADP, platelet de-aggregation in
the presence of the antibody was inhibited by 90%. Inhi-
bition of ADP-induced platelet aggregation by EMILIN2
antibody was dose dependent, with the highest inhibition
achieved at 26 μg/ml (Figure 4D). These data suggest
that EMILIN2 functions in stabilizing aggregated
platelets.
Discussion
In this study we report evidence that EMILIN2 may play
a role in thrombosis. EMILIN2 mRNA expression is
high in bone marrow and higher in macrophages than
endothelial cells or fibroblasts The protein distribution
of EMILIN2 in thrombi was similar to P-selectin, a mar-
ker for platelets suggesting EMILIN2 may be associated
with platelets. Further, EMILIN2 antibody increased pla-
telet de-aggregation. EMILIN2 could play a role in
thrombosis by maintaining th ev e s s e lw a l la r c h i t e c t u r e
as a component of vessel wall or in the regulation of the
platelet aggregation stability by virtue of its presence in
plasma and platelets. This is the first report of in vivo
protein expression of EMILIN2 in adult tissues and to
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Figure 2 Emilin2 mRNA Expression in Tissues and Mouse Cells. GAPDH from the same cDNA samples used as endogenous control. A.
Expression of Emilin2 in lung, heart, aorta and bone marrow cells was determined by real-time PCR. Aorta, n = 3; others, n = 5. The mRNA levels
are presented as fold change relative to lung. The values are mean ± SEM n = 3-5. B. Expression of Emilin2 in mouse cell lines. The mRNA levels
are presented as fold change relative to EOMA. EOMA, mouse endothelial cell line; NIH3T3, mouse fibroblast cell line; Raw264.7, mouse
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thrombosis.
While EMILIN2 has a high homology to EMILIN1 and
the molecular structures of EMILIN1 and EMILIN2 are
similar, there are distinctive molecular differences between
the two proteins. In addition, the pattern of mRNA expres-
sion in embryonic development [21] is different between
EMILIN1 and EMILIN2 and the expression pattern is also
different in adults [21]. The differences in molecular struc-
ture and expression suggest the proteins have different
functions. On the other hand, there are similarities as well.
EMILIN2 and EMILIN1 are extracellular matrix proteins
and are found in the vasculature. EMILIN1 deficiency dis-
rupts the structure of the vascular wall and impairs elasto-
genesis. A deficiency of other microfibril and elastin
associated molecules also disrupt elastogenesis, including
fibrillin-1, fibrillin-2, microfibril associated glycoprotein 1
(MAGP1) [29] and the fibulins 1-5 [21-26,30,31]. Fibulin 4
heterozygous mice (the null mutation is lethal) have pro-
longed clot stability in the tail-bleeding/rebleeding assay
(Hoover-Plow, J and Chen, Q, unpublished results).
MAGP1 deficient mice have delayed thrombotic occlusion
after vascular injury [29]. To determine whether EMILIN2
plays an important role in vascular structure and response
to vascular injury will require the construction of geneti-
cally modified mice.
Platelet may be a site producing or storing EMILIN2.
Multimerin1, another EMILIN protein, is stored in the
platelet alpha granules bound to Factor V and is released
upon platelet activation [20]. EMILIN2 could be a com-
ponent of platelet alpha granules or alternatively, plasma
EMILIN2 could bind to the platelets and exert an effect
on thrombus stability. Factor V, a cofactor needed for
thrombin generation, is present in both plasma and plate-
lets and may be taken up by the platelets [19].
All adult tissues that have been tested contain EMILIN2,
cochlear basement membrane [32], brain, spleen, liver [33]
and heart [34,35]. This would be expected of an ECM pro-
tein. In addition, a number of proteomic and microarray
studies of human tissues (Table 1) have identified EMI-
LIN2 in extracellular fluids (plasma, synovial, amniotic
and seminal plasma), stem cells (hematopoietic, mesench-
ymal, osteoblasts), stimulated endometrial stromal cells,
cancer cells (hepatic, lymphocytic leukemia, colorectal
cancer, and ovarian cancer), and as a cell surface marker
for human embryonic stem cell-derived cardiomyocytes
[36-50]. A recent study [40] reported down-regulation of
EMILIN2 in brain arteriovenous malformations. These
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Figure 3 Localization of EMILIN2 in carotids. A, B. Sections from uninjured carotid were immunostained with E185 for EMILIN2. C, D, E. Ferric
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software. Modified from Sa et al [Mamm Genome 2010 21:337-349].
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and pathological roles. The identification of EMILIN2 in
plasma in humans as well as a component of mouse
thrombus supports the hypothesis that EMILIN2 could
p l a yar o l ei nt h r o m b o s i s .
Conclusions
In this study, we found EMILIN2 expression in mouse
lung, heart, aorta, and bone marrow. Protein
expression in the carotid vessel wall and thrombi sug-
gesting EMILIN2 could function directly in the throm-
b u sa n d / o ra sac o n s t i t u e n to ft h ev e s s e lw a l l .
EMILIN2 was identified in humans in plasma/serum,
amniotic fluid, seminal plasma, stem cells, cancer cells,
and heart stem cells suggesting EMILIN2 may play
important physiological/pathological roles. Further stu-
dies, are needed to identify the role of EMILIN2 in
platelet aggregation.
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Figure 4 EMILIN2 antibody inhibited mouse platelet aggregation. A, B, C. Platelet aggregation in platelet-rich plasma was induced by ADP
and optically measured with an aggregometer. Platelets were pre-incubated with affinity purified rabbit anti-mouse EMILIN2 antibody (E185) or
rabbit IgG as a control. A. Representative aggregation curves are shown. B. Quantification of aggregation results expressed as maximal amplitude
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D. Representative platelet aggregation curves in platelet-rich plasma from B6-Chr17
A/J mice. Concentrations of EMILIN2 antibody are indicated.
Statistical differences between ADP or IgG and E185 were determined by ANOVA with a Newman-Kuels Multiple Comparison Test.
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Additional file 1: Figure 1: EMILIN2 peptide for antibody
generation. In order to measure EMILIN2 protein and to study its
functions, a polyclonal antibody for mouse EMILIN2 was generated in
rabbits. Since EMILIN2 has a high homology to EMILIN1, a peptide was
synthesized from residues 829-843 located in the proline-rich domain
specific to EMILIN2 (see additional file 1). To increase the specificity of
the antibody, the rabbit antiserum was subjected to affinity-purification
using the peptide.
Additional file 2: Figure 2: EMILIN2 antibody specificity. To test the
specificity of the antibody, HEK293 cells were transfected with the
construct E2-N1 that contains the EMILIN2-EGFP fusion gene and
construct PR-N1 that harbors the PR domain-EGFP fusion gene. The
vector N1 that contains only the EGFP gene was used as negative
control. Constructs containing EMILIN2 protein domains, namely
Collagen-like C1q domains that do not interact with the antibody, and
EGFP fusion genes, were also used as negative controls.
Additional file 3: Figure 3: EMILIN2 Immunostaining of aorta. After
cardiac perfusion, the aortas were harvested, immediately embedded
into OCT (Tissue-Tek, Torrance, CA) and frozen. The frozen aortas were
sectioned at 10 μm using a cryostat (Leica CM1850, Leica Microsystems,
Nassloch, Germany), fixed with acetone at 4°C for 10 min then blocked
with normal serum. EMILIN2 was detected with E185 antibody. The
section was then incubated with 1:1000 diluted biotinylated appropriate
secondary antibodies (PK-6101, PK-6105 Vectastain ABC Kit, Vector
Laboratories, Burlingame, CA) and EMILIN2 visualized (brown color) with
alkaline phosphatase substrate.
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